AVAX Technologies, Inc. Announces Collaboration With Cancer Treatment Centers Of America

Published: Feb 21, 2007

PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces it has executed a collaboration and production agreement with Cancer Treatment Centers of America, Inc. (CTCA) for AVAX’s O-Vax, the AC Vaccine Therapeutic for the treatment of Ovarian Cancer and for the production of CTCA’s activated natural killer (NK) cell technology for the treatment of various human cancers. AVAX intends to activate a Phase I/II IND for the treatment of Stage III & IV Ovarian Cancer patients who have relapsed following chemotherapy. In the planned study, AVAX will evaluate patients for safety and immunological responses, as measured by Delayed Type Hypersensitivity (DTH). The study will be centered in CTCA’s hospital in Zion, Illinois, although eligible patients also will be referred from CTCA’s other clinical centers in Tulsa, Philadelphia, and Seattle.

Back to news